NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that the China National Intellectual Property Administration has granted a new patent covering DUET-02, one of three key CpG-STAT3 inhibitors comprising the Duet Platform.
- The new patent covers the compound and composition, including phosphorothioated oligodeoxynucleotide, and methods of use for CpG-STAT3ASO, Duets CpG-STAT3 Antisense inhibitor.
- Alan Horsager, Ph.D., President and Chief Executive Officer of Duet and President Immuno-Oncology for Scopus, stated, This is an important milestone for Duet Therapeutics as we continue to build our patent portfolio.
- Dr. Horsager added, Duet continues to receive inbound inquiries regarding the Duet Platform from interested companies in Asia, including China.
- The new patent positions Duet Therapeutics, a wholly-owned subsidiary of Scopus, to pursue opportunities arising from Chinas burgeoning biotech market.